A US study has found five-year survival rates for US adolescents and young adults with cancer has improved from 1975 to 2005. However, improvement rates were linked to cancers such as leukeamia, non-Hodgkin lymphoma, Hodgkin lymphoma, CNS tumours, melanoma and other skin cancers, breast and kidney cancers, while other cancers did not improve. Queensland researchers have discovered a particular combination of common cancer treatments can have an exponentially more beneficial effect. |
| | | Monday 2 March - Tuesday 10 March |  |  | ABC News • Mar 9, 2020 16:50 |  | | Getty Images: CIPhotos 'Monoclonal antibodies' are immunotherapy drugs, designed to enlist the body’s immune system to fight cancer. They... Building better cancer treatments |
|
| | Small Caps • Mar 9, 2020 0:0 | | | Biotechnology company Immutep (ASX: IMM) has received approval from the US Food and Drug Administration for an investigational new drug... Immutep receives further FDA approval for efti cancer drug |
|
| | WAtoday.com.au (Licensed by Copyright Agency) • Mar 6, 2020 11:9 | | | For researcher Fiona Simpson, the fight against cancer is personal, and she hopes to land a knockout blow with a... results. Professor Simpson has spent the past decade on this research, driven by the death of her mother from cancer in... |
|
| | The Medical News • Mar 4, 2020 8:44 | | | The five-year survival rate for adolescents and young adults with cancer has significantly improved from 1975 to 2005 in the United States... Study: Five-year survival rate for adolescents and young adults with cancer has improved |
|
|
|
|
|
|
